Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma
Conditions
Keywords
70 years old, DLBCL, Rituximab-CHOP, Sarcopenia
Brief summary
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
Detailed description
Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
Interventions
PROCEDUREanthropometric measurement
To attest the muscular strength: hand grip test, balance test, up and go test
Sponsors
Centre Henri Becquerel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients \>= 70 years * DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade lymphoma * Whatever the IPI score and the performance status * Treated by Rituximab-CHOP or Rituximab-mini-CHOP * CT scan imaging performed one month or less before inclusion * Signed informed consent
Exclusion criteria
* No initial CT scan imaging performed more than one month before inclusion * Positivity for HCV, HBV and HIV * Anthracycline contra-indication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | at 18 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | at 24 months | — |
| rate of over grade 2 toxicities | at the first and second courses of chemotherapy (day 21 and day 42) | — |
| determination of both molecular subtypes GCB and ABC | at 24 months | according DASL technology (c-DNA mediated annealing selection extension and ligation) |
Countries
France
Outcome results
None listed